Investor Relations

SEC Filings

  o View CEL-SCI's SEC Filings  
       

Corporate Overview

  o View Corporate Overview  
       

CEL-SCI Presentations & Interviews

  February 2016
Geert Kersten as a featured guest on Fox Business' Making Money with Charles Payne

 
  January 2016
Interview with Dr. Eyal Talor, Chief Scientific Officer

 
  January 2016
Geert Kersten at the Noble Financial Capital Markets' 12th Annual Investor Conference

 

Warrant Quote

  o NYSE MKT: CVM WS  

 

Press Releases

  o All Press Releases  
 
  AUGUST 14, 2017
NEW STORY U.S. FDA Removes Clinical Hold on CEL-SCI's Phase 3 Head & Neck Cancer Trial
  AUGUST 9, 2017
NEW STORY CEL-SCI Extends the Expiration Date of Series DD Warrants Issued in December 2016
  AUGUST 9, 2017
NEW STORY CEL-SCI Corporation Reports Third Quarter Fiscal Year 2017 Financial Results
  JULY 6, 2017
NEW STORY CEL-SCI Extends the Expiration Date of Series DD Warrants Issued in December 2016
  JUNE 12, 2017
NEW STORY CEL-SCI Announces Reverse Stock Split
  JUNE 8, 2017
NEW STORY CEL-SCI Announces New Data for Its Rheumatoid Arthritis Vaccine Candidate Published in Peer Reviewed Journal
  JUNE 5, 2017
NEW STORY CEL-SCI Submits FDA Response for Its Phase 3 Head and Neck Cancer Trial
  MAY 24, 2017
NEW STORY CEL-SCI Corporation Releases Letter to Shareholders
  MAY 12, 2017
NEW STORY CEL-SCI Announces Change to the Date of Its Annual Meeting
  MAY 10, 2017
NEW STORY CEL-SCI Corporation Reports Second Quarter Fiscal Year 2017 Financial Results
  MAY 1, 2017
NEW STORY CEL-SCI Announces $1.51 Million Registered Direct Offering
  APRIL 28, 2017
NEW STORY CEL-SCI Receives Intent to Grant Notice for New Multikine Patent from the European Patent Office
  APRIL 24, 2017
NEW STORY CEL-SCI Corporation Releases Letter to Shareholders
  MARCH 9, 2017
NEW STORY CEL-SCI Announces $1.5 Million Registered Direct Offering
  MARCH 6, 2017
NEW STORY CEL-SCI Gives Update on Partial Clinical Hold on Phase 3 Head and Neck Cancer Study with Multikine
  FEBRUARY 27, 2017
NEW STORY CEL-SCI Announces That the NYSE MKT Approves Plan
  FEBRUARY 21, 2017
NEW STORY CEL-SCI Scientist Presents New Findings for Rheumatoid Arthritis Treatment Vaccine at Conference
  FEBRUARY 17, 2017
NEW STORY CEL-SCI Announces $1.0 Million Registered Direct Offering
  FEBRUARY 9, 2017
NEW STORY CEL-SCI Corporation Reports First Quarter Fiscal 2017 Financial Results
  DECEMBER 20, 2016
NEW STORY CEL-SCI Announces Closing of Public Offering and Receives Audit Opinion with Going Concern Explanation
  DECEMBER 14, 2016
NEW STORY CEL-SCI Reports Fiscal 2016 Financial Results and Clinical & Corporate Developments
  DECEMBER 2, 2016
NEW STORY CEL-SCI Announces Pricing of $4.25 Million Public Offering of Common Stock and Warrants
  NOVEMBER 21, 2016
NEW STORY CEL-SCI Submits Response to FDA in Connection with Partial Clinical Hold on Phase 3 Clinical Trial
  NOVEMBER 14, 2016
NEW STORY CEL-SCI Reports Preclinical Data Showing LEAPS Vaccine Is Successful In Treating Rheumatoid Arthritis
  OCTOBER 21, 2016
NEW STORY CEL-SCI Provides Update on Partial Clinical Hold on Phase 3 Clinical Trial
  SEPTEMBER 26, 2016
NEW STORY CEL-SCI Reports Clinical Hold on Head and Neck Cancer Study

Investor Relations Contact

   

Gavin de Windt
Phone: +1 703-506-9460
E-mail: gdewindt@cel-sci.com